StockMacro
Menu

Doximity

DOCS on XNYS, Doximity, Inc.

Measures activity, not value. Not investment advice.

Latest quarter (Jul 2026)

+3.6%

-13.2 pts vs its 3-year median

Sharp changes

0

quarterly revenue change, quarterly capital spending jump

Window

What usually follows Revenue growth was not followed by a clear share-price difference over the next 6 months. No relationship found How we measured it

Median revenue growth on a year earlier: +3.6% in the quarter from 1 Jul 2026 (3-year median +17%)

10-Q and 10-K figures, by the quarter they describe. Dashed: 3-year median.

See the numbers
Quarter of Jul 2026: +3.6%
Quarter of Apr 2026: +7.3%
Quarter of Jan 2026: +5.1%
Quarter of Oct 2025: +9.8%
Quarter of Jul 2025: +23%
Quarter of Apr 2025: +15%
Quarter of Jan 2025: +17%
Quarter of Oct 2024: +25%
Quarter of Jul 2024: +20%
Quarter of Apr 2024: +17%
Quarter of Jan 2024: +6.4%
Quarter of Oct 2023: +17%
Quarter of Jul 2023: +11%
Quarter of Apr 2023: +20%
Quarter of Jan 2023: +18%
Quarter of Oct 2022: +18%
Quarter of Jul 2022: +29%
Quarter of Apr 2022: +25%
Quarter of Jan 2022: +40%
Quarter of Oct 2021: +67%
Quarter of Jul 2021: +76%
Quarter of Apr 2021: +100%

What the numbers say

  • Median revenue growth on a year earlier: +3.6% in the quarter from 1 Jul 2026 (3-year median +17%).
  • Median growth on a year earlier, latest complete quarter: the largest is R&D expense, +39%.
Median growth on a year earlier, latest complete quarter: the largest is R&D expense, +39%
See the numbers
R&D expense+39%
Revenue+3.6%
Deferred revenue+0.2%

Every measure from this source

5 years, by the period each figure describes

Revenue (quarter). $661.6M in the last 12 months, +6.5% on the year before.
Capital spending (quarter). $62K in the last 12 months.
R&D expense (quarter). $154.1M in the last 12 months, +48% on the year before.
Deferred revenue (quarter end). $100.2M in the latest period, +0.2% on a year earlier.
Revenue (fiscal year). $644.9M in the last 12 months, +13% on the year before.
Capital spending (fiscal year). $0 in the last 12 months.
R&D expense (fiscal year). $130.7M in the last 12 months, +40% on the year before.

Sharp changes

0 in all loaded history, strongest first

No sharp change of this kind in all loaded history.

The records

One row per company, data through 1 Nov 2026

Showing 1 to 1 of 1.
CompanySectorLatest quartervs year before
DoximityTechnology$174.5M